•  
  •  
  •  
  •  

2026-07-24 12:08:11

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Mphasis Reports 17.5% YoY Revenue Growth in Q1 FY27; Secures $461 Million in New Deal Wins Driven by AI Demand
  • Fractal Analytics Reports 20% Revenue Growth and 92% Surge in Net Income for Q1 FY27
  • Route Mobile Ltd Financial Results Reveal Strong Operational Top-Line Expansion for Q1 FY27 as Revenue Reaches ₹1,151.51 Crore
  • CyberTech Systems and Software Limited Reports Q1 FY27 Net Profit Up 16% YoY to ₹9.48 Crore as Operational Revenue Reaches ₹68.45 Crore
  • ACME Solar operationalizes 3.62 GWh Battery Energy Storage System projects in Rajasthan

Keywords Selected:  Form483

Stock Report

  • Wanbury Limited gets 6 observations from USFDA after cGMP inspection at Tanuku facility
  • US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Amaliya, Daman
  • USFDA inspection at Somerset facility of Lupin Ltd
  • Granules India Limited completes cGMP Audit at its Chantilly Site
  • Unit-IV of APL Healthcare Ltd classified as VAI by the US FDA
  • Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
  • APL Healthcare Ltd's Unit-4 gets 5 observations from USFDA
  • Apitoria Pharma Pvt Ltd receives 3 observations from USFDA for Unit-V
  • Shilpa Medicare Ltd receives 8 observations from USFDA for Unit 4 at Jadcherla
  • Lupin Ltd receives 7 observations from USFDA for Goa manufacturing facility
  • Apitoria Pharma Pvt Ltd receives 5 observations from USFDA for API facility
  • Lupin receives Form 483 with 3 observations from USFDA for Pithampur Unit-3
  • Lupin receives Form 483 with 4 observations from USFDA for Pithampur Unit-2
  • Granules India Ltd receives 1 observation from USFDA for Chantilly facility
  • Unichem Laboratories Ltd receives Form 483 from USFDA with 3 observations for Roha API facility
  • Granules India Ltd receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
  • U.S. FDA inspection at Glenmark Pharma's Facility at Monroe, North Carolina, USA
  • Sun Pharma gets 8 observations from USFDA for Halol facility
  • Neuland Laboratories Ltd completes USFDA inspection at Unit 2
  • USFDA Inspection at Concord Biotech Ltd's API facility at Dholka
  • J B Chemicals & Pharmaceuticals Ltd successfully completes USFDA inspection at API facility
  • Indoco's Clinical Research Organisation - AnaCipher completes US FDA inspection
  • USFDA Inspection at Unit-1 of Shilpa Pharma Lifesciences Limited
  • USFDA inspection at Emcure Pharmaceuticals Ltd's API facility

Latest Post

  • Mphasis Reports 17.5% YoY Revenue Growth in Q1 FY27; Secures $461 Million in New Deal Wins Driven by AI Demand
  • Fractal Analytics Reports 20% Revenue Growth and 92% Surge in Net Income for Q1 FY27
  • Route Mobile Ltd Financial Results Reveal Strong Operational Top-Line Expansion for Q1 FY27 as Revenue Reaches ₹1,151.51 Crore
  • CyberTech Systems and Software Limited Reports Q1 FY27 Net Profit Up 16% YoY to ₹9.48 Crore as Operational Revenue Reaches ₹68.45 Crore
  • ACME Solar operationalizes 3.62 GWh Battery Energy Storage System projects in Rajasthan


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025